Update on Nasdaq initial public offering in the United States
As announced on 18 August 2021, Incannex Healthcare Limited (ASX: IHL, ‘Incannex’ or the ‘Company’) filed a registration statement on… Read more
Incannex – New Frontiers in Treatment
“Psychedelics, used responsibly and with proper caution, would be for psychiatry what the microscope is for biology and medicine, or… Read more
Incannex September 2021 Quarterly Activities Report and Appendix 4C
Highlights: • Phase 2a psilocybin-assisted therapy for Generalised Anxiety Disorder clinical trial has received approval to proceed from the Monash… Read more
Positive pre-IND meeting with US FDA and ethics approval to commence Phase 2a Psi-GAD clinical trial: psilocybin-assisted psychotherapy for Generalised Anxiety Disorder
Clinical stage pharmaceutical development company, Incannex Healthcare Limited (ASX: IHL, ‘Incannex’ or the ‘Company’), is pleased to announce: 1. that… Read more
Incannex engages Procaps to manufacture IHL-42X soft-gel capsules in preparation for pivotal clinical trials
Clinical stage pharmaceutical development company, Incannex Healthcare Limited (ASX: IHL, ‘Incannex’ or the ‘Company’), is pleased to announce that it… Read more
Incannex completes option exercise program to raise A$17.66 million; including A$8.20 million from Chief Medical Officer
Clinical stage cannabinoid and psychedelic medicine development company, Incannex Healthcare Limited (ASX: IHL, ‘Incannex’ or the ‘Company’) is pleased to… Read more
Incannex NOTICE OF EXTRAORDINARY GENERAL MEETING
Incannex files registration statement with the SEC for proposed initial public offering in the United States
